Metabolism of Testosterone in the Human Prostate and Seminal Vesicles

Abstract

Tissue from the normal, hyperplastic and the cancerous human prostate as well as tissue from the human seminal vesicles are capable of metabolizing testosterone in vitro.

By incubating minced tissue with ³H-testosterone for 2 hours at 37°C the following radioactive metabolites were identified: testosterone (17β-hydroxy-4-androsten-3-one), androstenedione (4-androstene-3, 17-dione), androstanedione (5α-androstane-3, 17-dione), 5α-dihydrotestosterone (17β-hydroxy-5α-androstane-3-one, DHT), 3α-androstanediol (5α-androstane-3α,17β-diol), 3β-androstanediol (5α-androstane-3β,17β-diol) and androsterone (3α-hydroxy-5α-androstane-17-one).

When normal human prostatic tissue was incubated with ³H-testosterone approximately 40% of the hormone was metabolized and 30-35% of the metabolites were identified as DHT. There were apparently no differences in testosterone metabolism between the dorsal and lateral prostatic lobes. A much lower conversion of ³H-testosterone was observed in the seminal vesicles (24%).

The same metabolites were formed by prostatic carcinoma tissue, although distinctive quantitative differences from the normal prostate were observed. Thus, only 23% of the testosterone was metabolized by cancerous tissue of which 15% was present as DHT. The formation of 17-keto metabolites and androstanediols in the prostatic carcinoma tissue was approximately the same as in the normal prostatic tissue.

The most extensive metabolism of testosterone was found by incubation of tissue from benign nodular prostatic hyperplasia. About 65% of the testosterone was metabolized, and 40% of the metabolites were identified as DHT. Hyperplastic prostatic tissue also showed a significantly higher formation of 5α-androstanediols than the other tissues examined.

The high formation of DHT and 5α-androstanediols in benign nodular prostatic hyperplasia in comparison with normal and cancerous prostatic tissue and seminal vesicle tissue might indicate that these metabolites should be studied more closely as possible aetiological factors for prostatic hyperplasia. The very low metabolism of testosterone in prostatic carcinoma tissue should be examined further in relation to tumour differentiation and clinical effect of endocrine therapy.